Skip to content

Prime Medicine, Inc.

PRME

CIK 0001894562

← back to feed
Revenue (TTM)
$4M
+55.3% YoY Q1 Apr 2026
Net Income (TTM)
−$204.19M
−2.7% YoY Q1 Apr 2026
EPS Diluted (TTM)
−$1.41
+18.2% YoY Q1 Apr 2026
Gross Margin
—
Q1 Apr 2026
Operating Margin
-5,256.0%
Q1 Apr 2026
Net Margin
-5,100.8%
Q1 Apr 2026
Free Cash Flow (TTM)
−$207.79M
Q1 Apr 2026
Cash
$64.11M
Q1 Apr 2026
Total Debt
—
Q1 Apr 2026
Shares Outstanding
180.62M sh
Q1 Apr 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings